GRAL
Company Description
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 147.17M | 125.59M | 93.11M | 55.55M | 14.61M | 0 | 0 | 0 |
| Net Income | (408.35M) | (2.03B) | (1.47B) | (5.40B) | (1.25B) | (312.16M) | (244.85M) | (275.72M) |
| EPS | -11.11 | -63.54 | -47.20 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 |
| Free Cash Flow | (299.01M) | (582.36M) | (608.69M) | (584.17M) | (758.06M) | (243.91M) | (249.13M) | (225.25M) |
| FCF / Share | -8.14 | -18.26 | -19.60 | -18.81 | -24.41 | -1.97 | -2.02 | -1.97 |
| Operating CF | (299.01M) | (577.16M) | (595.80M) | (561.31M) | (688.13M) | (232.00M) | (245.79M) | (209.26M) |
| Total Assets | 2.92B | 2.98B | 4.56B | 5.60B | 9.74B | 706.30M | 635.52M | 686.85M |
| Total Debt | 98.01M | 68.14M | 84.41M | 96.01M | 110.56M | 62.99M | 42.04M | 2.52M |
| Cash & Equiv | 249.73M | 214.23M | 97.29M | 241.60M | 221.16M | 170.19M | 143.19M | 95.09M |
| Book Value | 2.58B | 2.50B | 3.65B | 4.65B | 9.43B | 561.84M | 550.53M | 600.37M |
| Return on Equity | -0.16 | -0.81 | -0.40 | -1.16 | -0.13 | -0.56 | -0.44 | -0.46 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.69M | 40.78M | 43.60M | 36.19M | 35.54M | 31.84M | 38.25M | 28.65M | 31.97M | 26.72M | 30.33M | 20.72M |
| Net Income | (110.25M) | (93.19M) | (99.18M) | (88.98M) | (113.98M) | (106.21M) | (97.07M) | (125.69M) | (1.59B) | (218.91M) | (5.49M) | (891.45M) |
| EPS | -2.56 | -2.29 | -2.44 | -2.46 | -3.18 | -3.10 | -2.89 | -3.94 | -51.06 | -7.05 | -0.18 | -28.71 |
| Free Cash Flow | (81.16M) | (87.49M) | (62.97M) | (63.63M) | (77.33M) | (95.07M) | (93.79M) | (105.55M) | (173.19M) | (209.83M) | (132.79M) | (160.58M) |
| FCF / Share | -1.88 | -2.15 | -1.55 | -1.76 | -2.21 | -2.77 | -2.94 | -3.31 | -5.58 | -6.76 | -4.28 | -5.17 |
| Operating CF | (80.73M) | (86.99M) | (63.78M) | (63.24M) | (76.97M) | (95.01M) | (93.49M) | (104.58M) | (171.80M) | (207.29M) | (128.90M) | (157.51M) |
| Total Assets | 2.84B | 2.80B | 2.92B | 2.60B | 2.70B | 2.85B | 2.98B | 3.12B | 3.27B | 4.75B | 4.56B | N/A |
| Total Debt | 91.31M | 51.03M | 98.01M | 58.59M | 62.16M | 64.32M | 68.14M | 72.19M | 76.11M | 79.94M | 84.41M | N/A |
| Cash & Equiv | 55.65M | 69.34M | 249.73M | 126.89M | 127.43M | 133.90M | 214.23M | 853.55M | 958.85M | 974.10M | 97.29M | N/A |
| Book Value | 2.54B | 2.50B | 2.58B | 2.24B | 2.31B | 2.41B | 2.50B | 2.59B | 2.70B | 3.99B | 3.65B | N/A |
| Return on Equity | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 | -0.04 | -0.04 | -0.05 | -0.59 | -0.05 | -0.00 | N/A |
